Successful treatment with daptomycin and ceftaroline of MDR Staphylococcus aureus native valve endocarditis: a case report.

Details

Serval ID
serval:BIB_2B99F3F57E16
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Successful treatment with daptomycin and ceftaroline of MDR Staphylococcus aureus native valve endocarditis: a case report.
Journal
The Journal of antimicrobial chemotherapy
Author(s)
Duss F.R., Garcia de la Mària C., Croxatto A., Giulieri S., Lamoth F., Manuel O., Miró J.M.
ISSN
1460-2091 (Electronic)
ISSN-L
0305-7453
Publication state
Published
Issued date
01/09/2019
Peer-reviewed
Oui
Volume
74
Number
9
Pages
2626-2630
Language
english
Notes
Publication types: Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
The best therapeutic approach for treating MRSA endocarditis remains unknown, particularly in cases of high vancomycin MICs. We report here a case of daptomycin-non-susceptible, ceftaroline-resistant and fosfomycin-resistant MRSA native left valve endocarditis that was successfully treated with valve repair and a combination of high-dose daptomycin and ceftaroline.
Antimicrobial testing of the clinical strain was performed using Etest and microdilution broth methods. Time-kill and chequerboard methodologies were used to test the activity of antibiotic combinations.
By Etest, the MIC of vancomycin was 2 mg/L, the MIC of daptomycin was 2 mg/L, the MIC of fosfomycin was 1024 mg/L and the MIC of ceftaroline was 1.5 mg/L. At the standard inoculum (105 cfu/mL), the three combinations of daptomycin plus ceftaroline, cloxacillin or fosfomycin were synergistic and bactericidal. However, when these combinations were tested using a higher inoculum (108 cfu/mL), all combinations were synergistic, but only daptomycin plus ceftaroline had bactericidal activity.
These results confirmed a synergistic effect between daptomycin plus ceftaroline and increased bactericidal activity against MRSA, suggesting that this combination may be effective for the treatment of invasive MRSA infection. Our experience highlights the potential clinical use of synergy testing to guide difficult treatment decisions in patients with MDR MRSA infection.
Keywords
Aged, 80 and over, Anti-Bacterial Agents/therapeutic use, Cephalosporins/therapeutic use, Community-Acquired Infections/diagnosis, Community-Acquired Infections/drug therapy, Community-Acquired Infections/microbiology, Daptomycin/therapeutic use, Drug Synergism, Endocarditis/diagnosis, Endocarditis/drug therapy, Endocarditis/microbiology, Fosfomycin/pharmacology, Humans, Male, Methicillin-Resistant Staphylococcus aureus/drug effects, Microbial Sensitivity Tests, Staphylococcal Infections/diagnosis, Staphylococcal Infections/drug therapy, Staphylococcal Infections/microbiology
Pubmed
Web of science
Open Access
Yes
Create date
22/07/2019 17:18
Last modification date
29/08/2020 5:20
Usage data